Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Transitional Cell Carcinoma
Interventions
DRUG

Cabazitaxel

25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6

OTHER

Best Supportive Care

Best Supportive Care including single agent chemotherapy as determined by the patient's study physician

Trial Locations (1)

B15 2TH

University Hospitals Birmingham, Birmingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Dr Anjali Zarkar

OTHER